Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Frontotemporal dementia (FTD) is increasingly recognized as an important type of degenerative dementia but satisfactory pharmacological treatment has not yet been established. We examined the clinical effects of aripiprazole, a new antipsychotic with partial agonistic properties at serotonin 5-HT(1A) and dopamine D(2) receptors, in parallel with cortical glucose metabolism changes. We conducted a follow-up investigation of clinical status and (18)F-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET) in a 73-year-old male patient with FTD over a 13-month period. Under conventional drug treatment during the first 12 months a marked increase in dementia symptoms was observed. Frontal lobe glucose metabolism clearly decreased during this time period. Under consecutive treatment with aripiprazole a significant and stable improvement of clinical symptoms could be registered, while disturbed frontal glucose metabolism increased significantly. According to this case experience, further investigations should be undertaken to ascertain whether aripiprazole or other atypical antipsychotics with properties to improve impaired dopaminergic transmission in frontal brain regions could qualify for therapy of FTD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1995) · PubMed Central · doi:10.2967/jnumed.120.252510a · Cited by 996
Volkow, N. D., Wang, G.-J., Fowler, J. S., Telang, F., Maynard, L., Logan, J., Gatley, S. J., Pappas, N., Wong, C., Vaska, P., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.7.1173 · Cited by 281 · cited 1×
“…primarily affected in FTD (Rinne et al. 2002), and beneficial effects of methylphenidate in single patients with FTD (Goforth et al. 2004) were attributed to improved dopamine availability (Volkow et al. 2000) associated with enhanced attention, motivation, and working memory (Volkow et al. 2004).”
Background
Cited by
Frontotemporal Lobar Degeneration: Epidemiology, Pathophysiology, Diagnosis and Management
Rabinovici, G. D., & Miller, B. L. (2010) · CNS Drugs · doi:10.2165/11533100-000000000-00000 · Cited by 501
Frontotemporal Lobar Degeneration: Epidemiology, Pathology, Diagnosis and Management
Seltman, R. E., & Matthews, B. R. (2012) · CNS Drugs · doi:10.2165/11640070-000000000-00000 · Cited by 132
Development of disease-modifying drugs for frontotemporal dementia spectrum disorders
Panza, F., Lozupone, M., Seripa, D., Daniele, A., Watling, M., Giannelli, G., & Imbimbo, B. P. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0330-x · Cited by 122
Pharmacotherapy for Neuropsychiatric Symptoms in Frontotemporal Dementia
Le, C., & Finger, E. (2021) · CNS Drugs · doi:10.1007/s40263-021-00854-5 · Cited by 26
Metadata
- Authors
- Fellgiebel, A., Müller, M. J., Hiemke, C., Bartenstein, P., & Schreckenberger, M.
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2007-01
- Volume
- 8
- Issue
- 2
- Pages
- 123-126
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2127998963
- Cited by
- 58
- References
- 2
- FWCI
- 0.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. https://app.cochat.ai/papers/10.1080/15622970601016538
- The paper
- Fellgiebel, A., Müller, M. J., Hiemke, C., Bartenstein, P., & Schreckenberger, M. (2007). Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. The World Journal of Biological Psychiatry. https://doi.org/10.1080/15622970601016538
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.